Refining the Management of Prostate Imaging Reporting Category 3 Lesions through SelectMDx Urinary Biomarker Evaluation

Among patients with PI-RADS 3 lesions (n=40), a significant correlation between SelectMDx results and biopsy-confirmed clinically significant prostate cancer was observed. Clinically significant cancer was detected in 57.1% of patients with a positive SelectMDx result, compared to 18.2% in those with a negative result (p=0.031). The test demonstrated a sensitivity of 57.14%, a specificity of 81.82%, a positive predictive value of 40% and a negative predictive value of 90%, with an overall diagnostic accuracy of 77.5%. While age emerged as the only independent predictor in multivariate analysis, SelectMDx showed a strong potential to exclude malignancy and support more selective biopsy strategies.